乳腺癌中的生长抑素受体介导显像:放射性标记生长抑素受体拮抗剂是否有应用价值
该临床前研究比较了生长抑素受体激动剂与拮抗剂在乳腺癌中的靶向结合能力。结果显示,拮抗剂在40例人乳腺癌标本中的结合显著高于激动剂,中位比值3.39,并在小鼠模型中表现出更优的肿瘤显像效果。结论认为生长抑素受体拮抗剂有望用于乳腺癌显像。
要点
- 拮抗剂111In-DOTA-JR11在40例人乳腺癌标本中的结合显著高于激动剂111In-DOTA-Tyr3-octreotate(P<0.001)。
- 拮抗剂结合与激动剂结合的中位比值为3.39(四分位距2-5)。
- 小鼠模型注射后285分钟,拮抗剂肿瘤摄取显著高于激动剂(1.92±0.43 vs. 0.90±0.17 %ID/g,P=0.002)。
核心结论
- 生长抑素受体拮抗剂是乳腺癌显像的有前景候选药物。
研究设计与样本
- 临床前研究比较了111In-DOTA-Tyr3-octreotate(生长抑素受体激动剂)与111In-DOTA-JR11(生长抑素受体拮抗剂)在40例人乳腺癌标本中的结合,使用体外放射自显影法。
- 对6例患者来源异种移植物的组织材料分析了放射性标记激动剂与拮抗剂的结合。
- 选取雌激素受体阳性模型T126生成原位乳腺癌小鼠模型,注射177Lu-DOTA-Tyr3-octreotate或177Lu-DOTA-JR11后进行体内SPECT/MRI和生物分布研究。
- 进行了生长抑素受体2型(SSTR2)免疫染色以确认肿瘤细胞的SSTR2表达。
主要发现
- 111In-DOTA-JR11与人乳腺癌组织的结合显著高于111In-DOTA-Tyr3-octreotate(P<0.001)。
- 拮抗剂结合与激动剂结合的中位比值为3.39(四分位距2-5)。
- SSTR2免疫染色确认了肿瘤细胞上的SSTR2表达。
- 小鼠模型的SPECT/MRI显示拮抗剂肿瘤可视化更佳,与生物分布研究中注射后285分钟拮抗剂肿瘤摄取显著高于激动剂一致(每克组织注射剂量百分比:1.92±0.43 vs. 0.90±0.17;P=0.002)。
关键数值与推荐
- 40例人乳腺癌标本中,111In-DOTA-JR11结合显著高于111In-DOTA-Tyr3-octreotate(P<0.001)。
- 拮抗剂结合与激动剂结合的中位比值为3.39(四分位距2-5)。
- 小鼠模型注射后285分钟,拮抗剂肿瘤摄取为1.92±0.43 %ID/g,激动剂为0.90±0.17 %ID/g(P=0.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent studies have shown enhanced tumor targeting by novel somatostatin receptor (SSTR) antagonists compared with clinically widely used agonists. However, these results have been obtained mostly in neuroendocrine tumors, and only limited data are available for cancer types with lower SSTR expression, including breast cancer (BC). To date, two studies have reported higher binding of the antagonist than the agonist in BC, but in both studies only a limited number of cases were evaluated. In this preclinical study, we further investigated whether the application of an SSTR antagonist can improve SSTR-mediated BC imaging in a large panel of BC specimens. We also generated an in vivo BC mouse model and performed SPECT/MRI and biodistribution studies. Methods: Binding of 111In-DOTA-Tyr3-octreotate (SSTR agonist) and 111In-DOTA-JR11 (SSTR antagonist) to 40 human BC specimens was compared using in vitro autoradiography. SSTR2 immunostaining was performed to confirm SSTR2 expression of the tumor cells. Furthermore, binding of the radiolabeled SSTR agonist and antagonist was analyzed in tissue material from 6 patient-derived xenografts. One patient-derived xenograft, the estrogen receptor-positive model T126, was chosen to generate in vivo mouse models containing orthotopic breast tumors for in vivo SPECT/MRI and biodistribution studies after injection with 177Lu-DOTA-Tyr3-octreotate or 177Lu-DOTA-JR11. Results:111In-DOTA-JR11 binding to human BC tissue was significantly higher than 111In-DOTA-Tyr3-octreotate binding (P < 0.001). The median ratio of antagonist binding versus agonist binding was 3.39 (interquartile range, 2-5). SSTR2 immunostaining confirmed SSTR2 expression on the tumor cells. SPECT/MRI of the mouse model found better tumor visualization with the antagonist. This result was in line with the significantly higher tumor uptake of the radiolabeled antagonist than of the agonist as measured in biodistribution studies 285 min after radiotracer injection (percentage injected dose per gram of tissue: 1.92 ± 0.43 vs. 0.90 ± 0.17; P = 0.002). Conclusion: SSTR antagonists are promising candidates for BC imaging.
引用
- Dalm SU, Haeck J, Doeswijk GN, et al. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists? J Nucl Med. 2017. PMID: 28450563. doi:10.2967/jnumed.116.189035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。